Global languages
2008-07-15
Regulatory

CELLAVISION AB (publ) Interim report for the period January 1 - June 30, 2008

  •    Net sales for the period were SEK 41.3 million (34.1), an increase of 21 %, of which SEK 22.8 million in the second quarter (17.3).
  •    The operating profit for the period was SEK 2.8 million (-3.7) and for the second quarter SEK 1.5 million (-2.8).
  •    Earnings per share for the period were SEK 0.11 (-0.17).
  •    Cash and cash equivalents amounted to SEK 16.9 million (8.8) at the close of the interim period.
  •    The application for body fluids was launched and the first licenses sold.
  •    The company was selected as a supplier of automated image analysis in the procurement process for the Västra Götaland region in Sweden.
  •    CellaVision's products were approved for sale in China and the first order from an end-user was received.
  •    A major American commercial laboratory chain chose CellaVision® DM96 for 14 of its laboratories.
  •    A subsidiary was established in Japan.
    •  
     
      CellaVision in summary
     
     
      (MSEK)
     
     
    1 Jan-30 June 2008
    1 Jan-30 June 2007
    Full year 2007
      Net sales
    41.3
    34.1
    74.6
      Gross profit
    25.8
    19.8
    45.3
      Operating result
    2.8
    -3.7
    3.1
      Net result
    2.6
    -3.9
    2.6
      Cash flow
    0.6
    -8.0
      -0.4
     
     
    CEO's comment
    "The first six months are a continuation of 2007, focusing on new products, geographical expansion and positive earnings. We are continuing to grow and strengthen our position in important markets," says Yvonne Mårtensson, CEO of CellaVision.
     
    "The strategic initiative to increase sales in the USA by supplementing our distributor with our own organization has now resulted in the first salespeople being in place. We will also increase personnel in Canada and Japan. These initiatives will not, however, have any sales impact until later this year and we are trying to continue market investments in pace with increased sales.
     
    Product registration in China was completed during the reporting period and we received our first order. We are pleased to have obtained exposure in this market with great long-term potential. We have also received the first orders for the application for body fluids, which can be purchased for all existing and future DM96s."
     
     
    For further information, please contact: 
    Yvonne Mårtensson, CEO. Phone: +46 708 33 77 82, e-mail: yvonne.martensson@cellavision.se
    Johan Wennerholm, CFO. Phone: +46 708 33 81 68, e-mail: johan.wennerholm@cellavision.se
     
     
    Download the report by pressing the link below.

    Attachments

    Interim report for the period January 1 - June 30, 2008

    Share